Skip to main content

What type of drug is Zejula?

Medically reviewed by Judith Stewart, BPharm. Last updated on June 23, 2025.

Official Answer by Drugs.com

Zejula (niraparib) is an oral, once-daily poly(ADP-ribose) polymerase inhibitor (PARP inhibitor).

PARP, or poly(ADP-ribose) polymerase, is a protein that helps repair damaged DNA. PARP inhibitors are targeted therapies that are used in the treatment of certain cancers.

PARP inhibitors work by stopping the repair of the damaged DNA in cancer cells, resulting in the death of the cancer cells.

Zejula was the third PARP Inhibitor to be approved by the FDA.

PARP Inhibitor Indications
Lynparza (olaparib)
  • ovarian cancer
  • fallopian tube cancer
  • peritoneal cancer
  • breast cancer
  • pancreatic cancer
  • prostate cancer
Rubraca (rucaparib)
  • ovarian cancer
  • fallopian tube cancer
  • peritoneal cancer
  • prostate cancer
Zejula (niraparib)
  • ovarian cancer
  • fallopian tube cancer
  • peritoneal cancer
Talzenna (talazoparib)
  • breast cancer
  • prostate cancer

Zejula is indicated:

Related questions

Read next

What is Paxel called in the USA?

Paxel contains the medicine paclitaxel, which was sold under the brand names Onxol and Taxol in the USA Continue reading

How long does it take Lynparza (olaparib) to work?

It takes Lynparza between two months and five months to start working depending on what cancer it is being used to treat. Continue reading

Anthracycline Drugs for Chemo: How Do They Work?

Anthracycline chemotherapy drugs are potent cancer treatments derived from Streptomyces bacteria. These drugs work by binding to cancer cell DNA, preventing replication and stopping tumor growth. Continue reading

See also:

Related medical questions

Drug information

Related support groups